A log-dose-response study of xipamide and its effect on metabolic parameters.
An extended dose-response study with xipamide, using seven doublings of the dose, from 0.3125 to 40 mg/day at 4-week intervals, was carried out in 12 hypertensive patients. Blood pressure showed a progressive decline with doses from 5 to 20 mg, and 40 mg xipamide produced no greater fall. Some subjects showed a maximum fall in blood pressure with a single dose increase but most showed a declining blood pressure over two or more dose increases. Plasma urea increased with doses of 5-40 mg to a similar extent, but there was no fall in the mean potassium level except with the 40-mg dose. Urinary calcium was reduced (from 4.2 to 1.7 mmol/24 h) on the 40-mg dose and the corrected plasma calcium level rose from 2.28 to 2.32 mmol/l. Triglycerides, very-low-density lipoprotein cholesterol and plasma aldosterone increased at the maximum dose; the cholesterol ratio, however, was unchanged.
Owens
C W
CW
Department of Clinical Pharmacology, University College, London, UK.
Tomlinson
B
B
Liu
J B
JB
Graham
B R
BR
Gillham
C
C
Smith
C C
CC
Betteridge
D J
DJ
Prichard
B N
BN
D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004232:Diuretics / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004573:Electrolytes / Q000378:metabolism; D006728:Hormones / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D050356:Lipid Metabolism; D013997:Time Factors; D014988:Xipamide / Q000008:administration & dosage*
D004232:Diuretics; D004573:Electrolytes; D006728:Hormones; D014988:Xipamide